Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 4/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SCD | O00767 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4696635 | 0.84 | BRD4 (0.53) | HTTTP53MTNR1AMTNR1BMAPT | |
| SCHEMBL4693966 | 0.83 | MTNR1A (0.46) | MTNR1AMTNR1B | |
| SCHEMBL4699300 | 0.82 | MTNR1A (0.47) | MTNR1AMTNR1BNPC1 | |
| SCHEMBL6047802 | 0.80 | TSPO (0.53) | TP53RXFP1 | |
| SCHEMBL4693967 | 0.77 | POLB (0.52) | LMNAHTTMTNR1AMTNR1BMAPT | |
| SCHEMBL4696102 | 0.76 | ALDH1A1 (0.62) | HTTTP53MAPT | |
| SCHEMBL4696828 | 0.76 | MTNR1A (0.48) | LMNAMTNR1AMTNR1B | |
| SCHEMBL4780614 | 0.75 | TSPO (0.44) | MTNR1AMTNR1B | |
| SCHEMBL6047815 | 0.75 | MTNR1A (0.43) | LMNAMTNR1AMTNR1B | |
| SCHEMBL4696393 | 0.74 | ALDH1A1 (0.51) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | KCNH2, KCNH3, KCNN1 | LMNA 888/4885TSHR 3853/4885HTT 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.